295 related articles for article (PubMed ID: 30993446)
21. Cancer Stem Cells Equipped with Powerful Hedgehog Signaling and Better Epigenetic Memory: Avenues to Look for Cancer Therapeutics.
Tandon I; Waghmode A; Sharma NK
Curr Cancer Drug Targets; 2019; 19(11):877-884. PubMed ID: 31393247
[TBL] [Abstract][Full Text] [Related]
22. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
Carpenter RL; Ray H
Drug Saf; 2019 Feb; 42(2):263-279. PubMed ID: 30649745
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of Hedgehog signalling in cancer.
Marini KD; Payne BJ; Watkins DN; Martelotto LG
Growth Factors; 2011 Dec; 29(6):221-34. PubMed ID: 21875383
[TBL] [Abstract][Full Text] [Related]
24. A molecular dynamics approach to identify an oxysterol-based hedgehog pathway inhibitor.
Dash RC; Maschinot CR; Hadden MK
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):168-177. PubMed ID: 27825830
[TBL] [Abstract][Full Text] [Related]
25. Development of anticancer agents targeting the Hedgehog signaling.
Zhang X; Tian Y; Yang Y; Hao J
Cell Mol Life Sci; 2017 Aug; 74(15):2773-2782. PubMed ID: 28314894
[TBL] [Abstract][Full Text] [Related]
26. Nonclassical hedgehog-GLI signaling and its clinical implications.
Shevde LA; Samant RS
Int J Cancer; 2014 Jul; 135(1):1-6. PubMed ID: 23929208
[TBL] [Abstract][Full Text] [Related]
27. The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy.
Liu N; Zhao R; Ma Y; Wang D; Yan C; Zhou D; Yin F; Li Z
Curr Top Med Chem; 2018; 18(28):2380-2394. PubMed ID: 30430946
[TBL] [Abstract][Full Text] [Related]
28. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
[TBL] [Abstract][Full Text] [Related]
29. Development of taladegib as a sonic hedgehog signaling pathway inhibitor.
Jin G; Sivaraman A; Lee K
Arch Pharm Res; 2017 Dec; 40(12):1390-1393. PubMed ID: 29159582
[No Abstract] [Full Text] [Related]
30. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
31. Scaffold hopping approach to a new series of smoothened antagonists.
Lu W; Geng D; Sun Z; Yang Z; Ma H; Zheng J; Zhang X
Bioorg Med Chem Lett; 2014 May; 24(10):2300-4. PubMed ID: 24726807
[TBL] [Abstract][Full Text] [Related]
32. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
33. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
34. Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma.
Lo WW; Wunder JS; Dickson BC; Campbell V; McGovern K; Alman BA; Andrulis IL
Cancer; 2014 Feb; 120(4):537-47. PubMed ID: 24151134
[TBL] [Abstract][Full Text] [Related]
35. The intrahepatic signalling niche of hedgehog is defined by primary cilia positive cells during chronic liver injury.
Grzelak CA; Martelotto LG; Sigglekow ND; Patkunanathan B; Ajami K; Calabro SR; Dwyer BJ; Tirnitz-Parker JE; Watkins DN; Warner FJ; Shackel NA; McCaughan GW
J Hepatol; 2014 Jan; 60(1):143-51. PubMed ID: 23978713
[TBL] [Abstract][Full Text] [Related]
36. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
37. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors.
Queiroz KC; Spek CA; Peppelenbosch MP
Drug Resist Updat; 2012 Aug; 15(4):211-22. PubMed ID: 22910179
[TBL] [Abstract][Full Text] [Related]
38. A synthetic combinatorial approach to disabling deviant Hedgehog signaling.
Fan CW; Yarravarapu N; Shi H; Kulak O; Kim J; Chen C; Lum L
Sci Rep; 2018 Jan; 8(1):1133. PubMed ID: 29348431
[TBL] [Abstract][Full Text] [Related]
39. [Sonic Hedgehog signaling pathway: from embryology to molecular targeted therapies].
Watson S; Serrate C; Vignot S
Bull Cancer; 2010 Dec; 97(12):1477-83. PubMed ID: 21220225
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets?
Ruiz i Altaba A
Cancer Cell; 2008 Oct; 14(4):281-3. PubMed ID: 18835029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
